Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Nov 1.

Published in final edited form as: Antiviral Res. 2011 Aug 22;92(2):372–377. doi: 10.1016/j.antiviral.2011.08.004

Fig. 3 — Predicted plasma d4T (grey) and cellular d4T-TP (TP, black) concentrations are shown for individuals taking d4T (without indinavir) at dosages of: 40 mg twice a day (bid) (A) or 30 mg bid (B). Analogous predicted concentration are also shown for individuals taking d4T (with indinavir) at 40 mg bid (C), and 30 mg bid (D). Medians (solid curves), 5^th 25^th and 75^th and 95^th percentiles (dashed curves), were calculated using data from 2,000 simulated individuals from each cohort, and are plotted together with the K_i of d4T-TP versus wild type HIV-1 RT measured in vitro in the presence of competing thymidine-5′-triphosphate (TTP).

Fig. 3 — Predicted plasma d4T (grey) and cellular d4T-TP (TP, black) concentrations are shown for individuals taking d4T (without indinavir) at dosages of: 40 mg twice a day (bid) (A) or 30 mg bid (B). Analogous predicted concentration are also shown for individuals taking d4T (with indinavir) at 40 mg bid (C), and 30 mg bid (D). Medians (solid curves), 5^th 25^th and 75^th and 95^th percentiles (dashed curves), were calculated using data from 2,000 simulated individuals from each cohort, and are plotted together with the K_i of d4T-TP versus wild type HIV-1 RT measured in vitro in the presence of competing thymidine-5′-triphosphate (TTP).